CHCHD2 and Parkinson's disease

Puschmann, Andreas; Dickson, Dennis W; Englund, Elisabet; Wszolek, Zbigniew K; Ross, Owen A

Published in:
Lancet Neurology

DOI:
10.1016/S1474-4422(15)00095-2

2015

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
**CHCHD2 and Parkinson’s disease**


Authors:

Andreas Puschmann, MD (corresponding author)
Lund University, Department of Clinical Sciences, Lund, Neurology, and Department for Neurology, Skåne University Hospital
Getingevägen 4
22185 Lund, Sweden
Phone: 0046-46-171000
Email: Andreas.Puschmann@med.lu.se

Dennis W. Dickson, MD
Department of Neuroscience (Neuropathology)
Mayo Clinic Jacksonville
4500 San Pablo Road
Jacksonville, FL 32224, USA
Email: Dickson.Dennis@mayo.edu

Elisabet Englund, MD
Lund University, Department of Clinical Sciences, Lund, Oncology and Pathology, Sweden, and Department of Clinical Pathology, Skåne University Hospital, Sweden
Sölvegatan 24
22185 Lund, Sweden
Email: Elisabet.Englund@med.lu.se

Zbigniew K. Wszolek, MD
Department of Neurology
Mayo Clinic Jacksonville
4500 San Pablo Road
Jacksonville, FL 32224, USA
Email: Wszolek.Zbigniew@mayo.edu

Owen A. Ross, PhD
Department of Neuroscience
Mayo Clinic Jacksonville
4500 San Pablo Road
Jacksonville, FL 32224, USA
Email: Ross.Owen@mayo.edu
Funayama and colleagues recently identified a mutation in the CHCHD2 gene in a large Japanese family with autosomal dominant Parkinson's disease, increasing our knowledge on the monogenic causes of this disorder. They also found the same mutation (182C>T, Thr61Ile) in another family with autosomal dominant Parkinson’s disease; the mutation was detected not only in a man with familial disease but also in his brother, who had developed fine tremor at age 10, but had no Parkinsonism at 50 years of age.

On the basis of this finding, Funayama and colleagues suggested that a CHCHD2 mutation might also be the genetic cause in the Arkansas family that we have followed longitudinally and have described previously. The family is large, with affected individuals in six generations who have clinical parkinsonism, essential tremor, restless legs syndrome, and depression, alone or in various combinations. Signs of postural or action tremor were present in 25 family members, of whom six also had Parkinson's disease. Tremor started insidiously and in three cases during childhood, although it often remained mild.

Neuropathological examination of two family members showed spheroid pigment degeneration with ubiquitin-positive axonal spheroids in the pallidum and substantia nigra, TAR DNA binding protein 43-positive pathology in the basal ganglia, hippocampus, and brainstem, and only sparse Lewy bodies; both individuals had a combination of essential tremor, parkinsonism, and depression.

We identified similar neuropathology in an affected individual from the Swedish family F-081; members of this family had a similar clinical picture to the Arkansas family members. Six members in three generations had Parkinson's disease with an autosomal dominant pattern of inheritance; symptoms started between ages 55 and 63 years. Three patients with Parkinson's disease had resting tremor, one had severe tremor and received deep brain stimulation, and one had restless legs syndrome for several years before the onset of
parkinsonism. Three patients with parkinsonism had mild cognitive impairment, compared with only one patient in the Arkansas kindred. Neuropathology in one member with tremor-dominant parkinsonism and mild cognitive impairment showed diffuse Lewy body disease and arteriosclerotic vascular disease. Unusually, we found TAR DNA binding protein 43-positive neuronal cytoplasmic and intranuclear inclusions and dystrophic neurites in the hippocampus, but not in the cortex or amygdala, and only sparse lesions in the basal ganglia and brainstem; we did not detect any Alzheimer's pathology.

The entire coding sequence of the CHCHD2 gene was analysed in four individuals from the Arkansas family, including two with Parkinson's disease and two with essential tremor, and in two first-degree cousins with Parkinson's disease from the Swedish family F-081. The CHCHD2 Thr61Ile substitution was not identified and we did not detect any other mutation in the gene. Although not present in our families, we will be interested to see whether other research on CHCHD2 mutations will add to the slowly emerging knowledge about the genetics of essential tremor.

**Declaration of interests:**

The authors declare no competing interests.

**Disclosures:**

Dr. Puschmann reports grants from The Swedish Parkinson Foundation (Parkinsonfonden), grants from governmental funding for clinical research within the Swedish National Health Services (ALF), grants from Bundy Academy, Sweden, grants from The Swedish Parkinson Academy, during the conduct of the study; personal fees from Lundbeck AB, Sweden,
personal fees from Swedish National Board of Health and Welfare (Socialstyrelsen), outside the submitted work.

Dr. Wszolek reports partial grant support from NIH/NINDS P50 NS072187, and reports a gift in the form of grant support from Carl Edward Bolch, Jr., and Susan Bass Bolch.

Dr. Ross reports grants from NIH grants NS078086 and NS072187, grants from The Michael J. Fox Foundation, during the conduct of the study; and membership on the editorial boards of American Journal of Neurodegenerative disease, Molecular Degeneration, and Parkinsonism and Related Disorders and PLoS ONE.

Role of the funding sources:
The sources funding this study had no role in the writing of the manuscript or the decision to submit it for publication.

Authors’ contributions:
Andreas Puschmann: Literature search, data collection, data analysis, data interpretation, writing; Dennis W. Dickson: Data collection, data analysis, data interpretation, critical review of manuscript; Elisabet Englund: Data collection, data analysis, data interpretation, critical review of manuscript; Zbigniew K. Wszolek: Study design, data collection, data analysis, data interpretation, critical review of manuscript; Owen A. Ross, PhD: Study design, data collection, data analysis, data interpretation, critical review of manuscript.
References:


